Профілактика і лікування передтромботичних станів при цукровому діабеті (огляд літератури)

Посилання

• 1. Волков В.И., Запровальная О.Е., Ладний А.И. (2001) Коррекция тромботических нарушений при ишемической болезни сердца. Книга плюс, Киев, 112 с.
• 2. Ефимов А.С, Тронько Н.Д, Соколова Л.К. и др. (2007) Патогенез и лечение хронических осложнений сахарного диабета. Вісн. фармакології та фармації, 11: 27–34.
• 3. Малая Л.Т., Дыкун Я.В. (2003) Гемостаз и острые коронарные синдромы — от фундаментальных исследований к клинической практике. Кровообіг та гемостаз, 1: 26–33.
• 4. Сергієнко О.О. (1997) Практична діабетологія. Інститут ендокринології та обміну речовин ім. В.П. Комісаренка АМН України, Київ; Львів, 172 с.
• 5. Сергієнко О.О., Єфімов А.С., Єфімов Д.А., Сергієнко В.О. (2007) Діабетична кардіоміопатія. Кварт, Львів — Київ, 341 с.
• 6. Сергієнко О.О., Махневич Т.Р., Сергієнко В.О., Плешанов Є.В. (2005) Антиагреганти і морфо-функціональний стан тромбоцитів у хворих на цукровий діабет 2-го типу та ішемічну хворобу серця. Клін. ендокринологія та ендокринна хірургія, 2(11): 41–53.
• 7. American Diabetes Association (2003) Aspirin therapy in diabetes (Position Statement). Diabetes Care, 26(suppl. 1): S87–S88.
• 8. American Diabetes Association (2008) Standards of medical care in diabetes — 2008. Diabetes Care, 31(Suppl. 1): S12–S54 [см. с. S27–S28] (http://care.diabetesjournals.org/content/31/Supplement_1/S12.full.pdf).
• 9. Beckman J.A., Creager M.A., Libby P. (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 287(19): 2570–2581.
• 10. Breckenridge A.M. (1978) Oral anticoagulant drugs: pharmacokinetic aspects. Semin. Hematol., 15: 19–26.
• 11. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association (1998) Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart, 80 (suppl. 2): S1–S29.
• 12. Chan P., Pan W.H. (1995) Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diab. Med., 12(6): 504–507.
• 13. Chen Z.M., Jiang L.X., Chen Y.P. et al.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute infarction: randomized placebo-controlled trial. Lancet, 366(9497): 1607–1621.
• 14. Clarke T.А., Waskell L.А. (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3А and is inhibited by atorvastatin. Drug. Metab. Dispos., 31(1): 53–59.
• 15. Dandona P., Aljada A., Chaudhuri A., Bandyopadhyay A. (2003) The potential influence of inflammation and insulin resistance of the pathogenesis and treatment atherosclerosis-related complications in type 2 diabetes. J. Clin. Endocrinol. Metabol., 88(6): 2415–2429.
• 16. Haffner S.M., Lehto S., Rönnemaa T. et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339(4): 229–234.
• 17. Hankey G.J., Sudlow C.L., Dunbabin D.W. (2000) Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev., 2: CD001246.
• 18. Hirsh J., Guyatt G., Albers G.W., Schünemann H.J. (2004) The seventh ACCP conference on antithrombotic and thrombolytic therapy. Evidence-based guidelines. CHEST, 126: 172S–173S.
• 19. Lau W.C., Gurbel PA, Watkins P.B. et al. (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 109: 166–171.
• 20. Meade T.W., Mellows S., Brozovic M. et al. (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, 2(8506): 533–537.
• 21. Moien-Afshari F., Ghosh S., Elmi S. et al. (2008) Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. Diabetologia, 51(7): 1327–1337.
• 22. Pearson T.A., Blair S.N., Daniels S.R. et al. (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation, 106(3): 388–391.
• 23. Pitsavos C., Panagiotakos D.B., Chrysohoou C. et al. (2005) The associations between physical activity, inflammation and coagulation markers, in people with metabolic syndrome: the ATTICA study. Eur. J. Cardiovasc. Prev. Rehabil., 12(2): 151–158.
• 24. Ridker P.M., Hennekens C.H., Cerskus A., Stampfer M.J. (1994) Plasma concentrations of cross-linked fibrin degradation product (D-Dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation, 90(5): 2236–2240.
• 25. The Medical Research Council’s General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet, 351: 233–241.
• 26. World Health Organization (1990) Definition diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org.,
• 27. Yusuf S., Zhao F., Mehta S.R. et al.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 345: 494–502.